Patricia Inacio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inacio

Alzheimer’s Therapy Candidate Bryostatin Generates New Synapses in Mouse Brains, Study Shows

Neurotrope Bioscience’s lead Alzheimer’s drug candidate, bryostatin, promotes the formation of new synapses in the brains of mice, according to the study, “PKC epsilon Promotes Synaptogenesis through Membrane accumulation of the Postsynaptic Density Protein PSD-95,” recently published in the Journal of Biological Chemistry. Synaptogenesis and synaptic maturation are two…

Certain Cells in Brain Likely Trigger Alzheimer’s Disease

In a new study titled “Identification of Vulnerable Cell Types in Major Brain Disorders Using Single Cell Transcriptomes and Expression Weighted Cell Type Enrichment,” researchers pinpointed microglia cells in the brain as the specific cell type that likely triggers not only Alzheimer’s disease, but also multiple sclerosis.

Researchers Identify Genes That Delay Alzheimer’s Disease

Researchers have discovered a network of nine genes that play a key role in Alzheimer’s disease onset. The study entitled “APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease” was published in the journal Molecular Psychiatry. Alzheimer’s disease age of onset varies greatly between individuals, a phenotype…

Neuroinflammation in Alzheimer’s Is Again a Therapy Target

Neuroinflammation in the central nervous system is a known key event in Alzheimer’s pathogenesis and has long been proposed as a therapeutic target, but studies conducted in the early 2000s of potential anti-inflammatory treatments didn’t produce the hoped for outcomes. Now a renewed interest is emerging in Alzheimer’s disease (AD) treatments targeting neuroinflammation, still a…